Ibrutinib in patients with refractory follicular lymphoma (#496).
Laufzeit: 01.01.2013 - 31.12.2016
imported
Kurzfassung
An open-label, multicenter, single-arm, phase II study of Ibrutinib (PCI-32765) in subjects with refractory follicular lymphoma
